Patients with chronic hepatitis C (HCV) infection and severe renal impairment respond well to a combination of glecaprevir and pibrentasvir, according to a recent open label clinical trial. Among the findings:

• 104 adult patients were enrolled in the trial, which lasted 12 weeks.
• HCV infections included genotypes 1, 2, 3, 4, 5, or 6; all patients had compensated liver disease with or without cirrhosis.
• Patients had severe renal disease or required dialysis, or both.
• Previous treatment for HCV was either non-existent or consisted of interferon or pegylated interferon, ribavirin, sofosbuvir, or a combination of these agents.
• 102/104 patients experienced a sustained virologic response to glecaprevir/pibrentasvir.
• Adverse reactions that occurred in at least 10% of patients included pruritus, fatigue, and nausea.